Stockreport

BRIEF-Psivida's Second Phase 3 Study For Durasert Three-Year Treatment For Posterior Segment Uveitis Maintains Positive Efficacy And Safety Profile At 12 Months [Reuters]

PSIVIDA  (PSDV) 
Last psivida earnings: 2/7 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.psivida.com
PDF BRIEF-Psivida's Second Phase 3 Study For Durasert Three-Year Treatment For Posterior Segment Uveitis Maintains Positive Efficacy And Safety Profile At 12 Months | Reuter [Read more]